Fibrosarcoma - Pipeline Review, H2 2016
SKU ID :GMD-10276454 | Published Date: 17-Aug-2016 | No. of pages: 64Description
TOC
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fibrosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Fibrosarcoma - Overview 8
Pipeline Products for Fibrosarcoma - Comparative Analysis 9
Fibrosarcoma - Therapeutics under Development by Companies 10
Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Fibrosarcoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Fibrosarcoma - Products under Development by Companies 15
Fibrosarcoma - Products under Investigation by Universities/Institutes 16
Fibrosarcoma - Companies Involved in Therapeutics Development 17
Advanced Proteome Therapeutics Corporation 17
Advenchen Laboratories, LLC 18
Daiichi Sankyo Company, Limited 19
Elsalys Biotech SAS 20
Millennium Pharmaceuticals Inc 21
Novartis AG 22
Rigontec GmbH 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Fibrosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AL-3818 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
APC-103 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Cellular Immunotherapy for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
DSR-6434 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
everolimus - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ImOl-100 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LK-3 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MAT-303 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
PLX-7486 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
sapanisertib - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SEN-461 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SOM-0777 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Fibrosarcoma - Dormant Projects 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
Tables & Figures
List of Tables
Number of Products under Development for Fibrosarcoma, H2 2016 8
Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2016 17
Fibrosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 18
Fibrosarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19
Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H2 2016 20
Fibrosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21
Fibrosarcoma - Pipeline by Novartis AG, H2 2016 22
Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2016 23
Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Fibrosarcoma - Dormant Projects, H2 2016 62
List of Figures
Number of Products under Development for Fibrosarcoma, H2 2016 8
Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
Companies
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
Daiichi Sankyo Company, Limited
Elsalys Biotech SAS
Millennium Pharmaceuticals Inc
Novartis AG
Rigontec GmbH
Sumitomo Dainippon Pharma Co., Ltd.
- PRICE
-
$2000$6000